N4-Cyclopropyl-N2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine

ID: ALA4777354

PubChem CID: 118905869

Max Phase: Preclinical

Molecular Formula: C15H11F5N4O2

Molecular Weight: 374.27

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC1(F)Oc2ccc(Nc3ncc(C(F)(F)F)c(NC4CC4)n3)cc2O1

Standard InChI:  InChI=1S/C15H11F5N4O2/c16-14(17,18)9-6-21-13(24-12(9)22-7-1-2-7)23-8-3-4-10-11(5-8)26-15(19,20)25-10/h3-7H,1-2H2,(H2,21,22,23,24)

Standard InChI Key:  ACIBBWPFHYLNQW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   16.4842   -8.1183    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   15.7784   -7.7097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7774   -8.5252    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   12.6568   -3.1532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6556   -3.9727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3637   -4.3817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.0734   -3.9722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0705   -3.1496    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.3619   -2.7443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9490   -2.7447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9488   -1.9275    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.2414   -3.1535    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.2384   -2.3360    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.9476   -4.3807    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7817   -4.3797    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7830   -5.1969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0746   -5.6050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0755   -6.4215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4894   -5.6006    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4938   -6.4157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7870   -6.8325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9650   -7.6336    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.1086   -6.9592    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.9470   -5.1979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5387   -5.9076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3559   -5.9082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  4 10  1  0
 10 11  1  0
 10 12  1  0
 10 13  1  0
  5 14  1  0
  7 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 21  2  0
 20 19  2  0
 19 16  1  0
 20 21  1  0
 21 22  1  0
 22  2  1  0
  2 23  1  0
 23 20  1  0
 14 24  1  0
 25 24  1  0
 26 25  1  0
 24 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4777354

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 374.27

Molecular Weight (Monoisotopic): 374.0802

AlogP: 4.13

#Rotatable Bonds: 4

Polar Surface Area: 68.30

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.55

CX Basic pKa: 4.21

CX LogP: 4.60

CX LogD: 4.59

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.78

Np Likeness Score: -1.41

References

1. Ren H,Bakas NA,Vamos M,Chaikuad A,Limpert AS,Wimer CD,Brun SN,Lambert LJ,Tautz L,Celeridad M,Sheffler DJ,Knapp S,Shaw RJ,Cosford NDP.  (2020)  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.,  63  (23): [PMID:33200929] [10.1021/acs.jmedchem.0c00873]

Source

Source(1):

• Scientific Literature